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Trifunctional protein deficiency/Long-chain hydroxyacyl-CoAdehydrogenase deficiency (LCHAD/TFP) deficiency
is a disorder of fatty acid oxidation and ketogenesis. Severe neonatal lactic acidosis, cardiomyopathy, and hepatic
dysfunction are caused by the accumulation of toxic long-chain acylcarnitines. The feasibility of umbilical cord
blood use in screening for acylcarnitine analysis and free carnitine has been hypothesized but not reported in
LCHAD/TFP neonates.
We present a 4 week old female who was at risk of inheriting LCHAD/TFP deficiency and was diagnosed at the
time of delivery using umbilical cord blood. Umbilical cord blood was collected at delivery and sent for
acylcarnitine analysis. Treatment was started immediately. Acylcarnitine analysis demonstrated findings that
are consistent with a biochemical diagnosis of LCHAD/TFP deficiency.
Patients with LCHAD/TFP deficiency should have treatment initiated as early as possible to avoid acute decom-
pensation and minimize the long-term complications of the disorder including cardiomyopathy. In pregnancies
at risk of having a child with LCHAD/TFP deficiency, umbilical cord blood sample is an efficient method to diag-
nose an inborn error of metabolism such as LCHAD/TFP deficiency.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Objective
To describe the diagnosis of Long-chain hydroxyacyl-CoA dehydro-
genase (LCHAD) deficiency using umbilical cord blood at the time of de-
livery in an at-risk pregnancy.
2. Introduction
Long-chain hydroxyacyl-CoA dehydrogenase deficiency is a disorder
of fatty acid oxidation and ketogenesis. Accumulation of toxic long-
chain acylcarnitines in LCHADdeficiencymay cause severe neonatal lac-
tic acidosis, cardiomyopathy, and hepatic dysfunction. Patientsmay also
manifest chronic weakness, pain, as well as recurrent rhabdomyolysis.
Patients may have acute decompensations with episodes of illness, de-
creased oral intake, prolonged fasting episodes, surgery, etc. Mothers
of affected fetuses can present with acute fatty liver of pregnancy or
HELLP syndrome [1].
“Mitochondrial trifunctional protein is composed of four alpha-sub-
units and four beta-subunits; the alpha-subunit has long-chain enoyl-
CoA hydratase (LCEH) and LCHAD activities, and the beta-subunit has
long-chain ketoacyl-CoA thiolase (LCKAT) activity” [1]. Isolated LCHAD
deficiency typically presents with hypoglycemia as well as liver dys-
function, lactic acidosis, and cardiomyopathy. As the patients age, they
can also develop feeding difficulties, rhabdomyolysis, hypoparathyroid-
ism, and retinopathy [1]. Mitochondrial Trifunctional Protein deficiency
is a more heterogeneous condition, which can range frommilder to se-
vere [1]. The milder phenotype can consist of exercise induced rhabdo-
myolysis and/or peripheral neuropathy to a more severe phenotype
similar to isolated LCHAD deficiency [1].
Patients can be identified through newborn screening with initi-
ation of appropriate interventions. The confirmatory testing for the
diagnosis is acylcarnitine profile analysis. Patients affected with
LCHAD deficiency have increased hydroxycompounds C14-OH,
C16-OH, C18-OH, and C18:1-OH. Urine organic acids demonstrate
C6-C14 hydroxydicarboxylic acids. Although patients identified
presymptomatically and treated can have a milder course, patients
with LCHAD deficiency can still develop chronic complications in-
cluding cardiomyopathy.
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Treatment consists of limiting dietary fat and providing other es-
sential nutrients in the formula and fasting avoidance. Due to in-
creased renal excretion of bound acylcarnitines, patients may
develop a secondary carnitine deficiency. Carnitine can be provided
if the patient is found to be deficient [2]. Aggressive treatment of car-
diomyopathy, rhabdomyolysis, and retinopathy are essential for op-
timal quality of life.
There are several studies including the one by Neto, et al. that dem-
onstrate the feasibility of umbilical cord blood use in screening for
acylcarnitine and free carnitine [3]. These studies used umbilical cord
blood that was placed on filter paper for analysis. In comparison to reg-
ularly timed newborn screening, the earlier screening using umbilical
cord blood could potentiallymiss some diagnoses that require ingestion
of breast milk or formula before the values start rising. There is one ab-
stract reporting clinical utility of umbilical cord blood in diagnosis of
high-risk neonateswith isovaleric acidemia andmedium-chain acyl-co-
enzyme A dehydrogenase deficiency [4].
To date, there are no published cases of LCHAD/TFP deficiency diag-
nosed using umbilical cord blood.
3. Clinical case
3.1. Clinical presentation
Our patient is a 4week-old femalewith LCHADdeficiency diagnosed
at the time of delivery using umbilical cord blood. Concern for the diag-
nosis of LCHADdeficiencywas suspected due to an affected older sibling
diagnosed through routine newborn screening. Her older sister was
found to have one pathogenic change in HADHB and no changes in
other genes associated with LCHAD deficiency; thus, shewas diagnosed
with LCHAD deficiency secondary to trifunctional protein (TFP) defi-
ciency. Our patient is a 4 week-old female with LCHAD deficiency diag-
nosed at the time of delivery using umbilical cord blood. Concern for the
diagnosis of LCHAD deficiency was suspected due to an affected older
sibling diagnosed through routine newborn screening. Her older sister
was found to have one pathogenic change in HADHB and no changes
in other genes associated with LCHAD deficiency; thus, she was diag-
nosed with LCHAD deficiency secondary to trifunctional protein (TFP)
deficiency. The older sibling had a complex neonatal course due to feed-
ing intolerance and lactic acidosis before discharge from the birth. Her
lactic acidosis led to a prolonged neonatal intensive care unit hospitali-
zation. Her newborn screen was notable for elevations concerning for
LCHAD deficiency and this was confirmed using acylcarnitine profile
testing. Her cardiac evaluation was normal. Due to the complex neona-
tal course and feeding intolerance, a gastric tube (G-tube) was placed
prior to her discharge from the birth hospital. Her first year of life was
notablewith feeding intolerance requiring G-tube feeds. Her first hospi-
talization with creatinine kinase elevation in the setting of mild illness
was at 12 months of age. Her cardiac evaluation remained normal.
Her mother was counseled on invasive prenatal testing; however,
due to the limited information that could be obtained prenatally, the
testing was declined. Pregnancy was complicated by late pregnancy
swelling, hypertension, and elevated liver function levels both before
and after delivery, suggestive of a diagnosis of HELLP syndrome.
The neonate was delivered at 37 weeks gestation. Umbilical cord
bloodwas collected at delivery and sent for acylcarnitine analysis. Treat-
ment was started immediately at delivery, including dextrose-contain-
ing fluids and Lipistart formula, a low long chain fat, high medium
chain fat formula.
3.2. Laboratory findings
Acylcarnitine analysis from the umbilical cord blood was significant
for C14-OH 0.14 nmol/mL (normal b0.04 nmol/mL), C16-OH 0.50 (nor-
mal b0.10), C18:2-OH 0.23 (normal b0.04), and C18:1-OH0.39 (normal
b0.03). These findings are consistent with a biochemical diagnosis of
LCHAD/TFP deficiency. Acylcarnitine analysis from the umbilical cord
blood was significant for C14-OH 0.14 nmol/mL (normal b0.04 nmol/
mL), C16-OH 0.50 (normal b0.10), C18:2-OH 0.23 (normal b0.04), and
C18:1-OH 0.39 (normal b0.03). These findings are diagnostic for
LCHAD deficiency. The newborn screen performed at 1 h of life from a
heel stick showed C16-OH 0.88 μmol/L (b0.10) and C18:1-OH
0.39 μmol/L (b0.11). Repeat newborn screen at day 7 of life after initia-
tion of formula containing high medium chain and low long chain fat
flagged as abnormal for the following: C16-OH 0.29 μmL/L, C18:1-OH
0.48 μmol/L, and C10 0.55 μmol/L (b0.10). Plasma acylcarnitine profile
performed at 4 weeks of life showed similar elevations with C16-OH
0.53 μmol/L (b0.06) and C18:1-OH 0.28 μmol/L (b0.03).
Creatine kinase remained elevated throughout her 17 day stay in the
intensive care unit with maximum noted on 2 days of life at 363 unit/L
(29–168) and improved prior to discharge.
Molecular testing was performed to identify any genetic changes
in the genes associated with LCHAD deficiency. Both siblings were
found to have a single change in the HADHB gene, c.1059delT, a likely
pathogenic variant identified in one previous publically reported da-
tabase. A follow-up microarray analysis did not indicate an exon de-
letion in the HADHB gene. Gene sequencing of the other causative
genes in fatty acid oxidation disorders were also performed to en-
sure that an alternate diagnosis was not the cause of the sibling's bio-
chemical diagnosis. These genes included ACAD9, ACADVL, AGA,
AP3B1, BLNK, CASP10, CD40, CD79A, CXCR4, ELANE, FMO3, G6PC3,
GATA1, GATA2, FGI1, GSS, HADHA, HAX1, ICOS, IGHM, PIK3R1, PNP,
RFX5, RFXANK, RFXAP, RMRP, RPS19, SDBS, SLC35A1, SMARCAL1,
STK4, STX11, VPS13B, WAS.
4. Discussion
Patients with LCHAD/TFP deficiency should have treatment initiated
as early as possible to avoid orminimize the long-term complications of
the disorder including cardiomyopathy. Standard newborn screening
using a dried blood spot is performed after 24 h of life and mailed to
the state laboratory. This delay in recognition and treatment of this dis-
order can result in irreversible damage.
Walter et al. (2009) [5] and Neto et al. [3] have demonstrated
acylcarnitine analysis using umbilical cord blood spots to be technically
feasible but they were not able to justify its use clinically. Although the
studies by Walter et al. were positively able to identify affected new-
bornswith umbilical cord blood spot analysis, therewere some patients
who had a negative screen who subsequently were diagnosed with a
metabolic condition [5].
The role of thematernal environment leading to abnormal newborn
screening results has been hypothesized. Multiple groups have shown
complex prenatal, transition, and early infancy carnitine fluctuations
[6–9]. This case shows that even as early as delivery, the neonatal me-
tabolism of carnitine species ismarkedly abnormal from normal ranges.
In the case presented here, whole umbilical cord blood, newborn
screening at time of delivery, newborn screening at seven days of life,
and plasma acylcarnitine analysis at 4 weeks of life. Although umbilical
cord blood has been demonstrated to be reliable in diagnosis in some
conditions, other conditions require time outside of the maternal envi-
ronment to accumulate metabolites therefore traditional newborn
screening cannot be currently replaced by umbilical cord blood
sampling.
5. Conclusions
In pregnancies at risk of having a childwith LCHAD deficiency due to
TFP deficiency, umbilical cord blood sample is an efficient method to di-
agnose an inborn error ofmetabolismwhen other prenatalmechanisms
are not available or reliable for a family.
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